On Monday, ARS Pharmaceuticals Inc (NASDAQ: SPRY) was 6.83% up from the session before settling in for the closing price of $13.33. A 52-week range for SPRY has been $2.55 – $13.72.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Over the past five-year period, the drop rate of yearbook sales for the company of the Healthcare sector was -34.76%. When this article was written, the company’s average yearly earnings per share was at -16.23%. With a float of $47.58 million, this company’s outstanding shares have now reached $96.41 million.
Considering the fact that the conglomerate employs 26 people, you should pay attention to its efficiency factor. In terms of profitability, gross margin is 86.81%, operating margin of -12071.49%, and the pretax margin is -9536.81%.
ARS Pharmaceuticals Inc (SPRY) Breakdown of a Key Holders of the stock
Also, it is sometimes useful to examine the sentiment of large-scale investors toward ARS Pharmaceuticals Inc stocks. The insider ownership of ARS Pharmaceuticals Inc is 50.92%, while institutional ownership is 37.74%. The most recent insider transaction that took place on Aug 19 ’24, was worth 140,000. Before that another transaction happened on Aug 13 ’24, when Company’s Chief Operating Officer sold 30,000 for $13.00, making the entire transaction worth $390,000. This insider now owns 6,024 shares in total.
ARS Pharmaceuticals Inc (SPRY) Recent Fiscal highlights
According to the Wall Street analysts, stocks earnings will be around -16.23% per share during the next fiscal year.
ARS Pharmaceuticals Inc (NASDAQ: SPRY) Trading Performance Indicators
You can see what ARS Pharmaceuticals Inc (SPRY) is doing with its current performance indicators. In the most recent quarter, the stock posted a quick ratio of 32.78. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 2760.85.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.47, a number that is poised to hit -0.15 in the next quarter and is forecasted to reach -0.88 in one year’s time.
Technical Analysis of ARS Pharmaceuticals Inc (SPRY)
Compared to the last year’s volume of 0.67 million, its volume of 2.11 million showed improvement in the last five days. As of the previous 9 days, the stock’s Stochastic %D was 95.28%. Additionally, its Average True Range was 0.86.
During the past 100 days, ARS Pharmaceuticals Inc’s (SPRY) raw stochastic average was set at 98.38%, which indicates a significant increase from 97.98% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 100.76% in the past 14 days, which was higher than the 62.13% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $10.08, while its 200-day Moving Average is $7.93. Nevertheless, the first resistance level for the watch stands at $14.65 in the near term. At $15.06, the stock is likely to face the second major resistance level. The third major resistance level sits at $15.77. If the price goes on to break the first support level at $13.53, it is likely to go to the next support level at $12.82. Now, if the price goes above the second support level, the third support stands at $12.41.
ARS Pharmaceuticals Inc (NASDAQ: SPRY) Key Stats
There are 96,895K outstanding shares of the company, which has a market capitalization of 1.38 billion. As of now, sales total 30 K while income totals -54,370 K. Its latest quarter income was 500 K while its last quarter net income were -12,520 K.
